Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.69 (
BMT
)
2,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Basic fibroblast growth factor
(
bFGF
) inhibits radiation-induced apoptosis, and radioprotects haematopoietic, cartilage growth plate, pulmonary and gastrointestinal tissues. Conversely, chronic overexpression of
bFGF
may promote fibrosis. We measured the endogenous circulating
bFGF
in blood of patients undergoing conditioning TBI. Twenty-six patients with haematopoietic malignancies were conditioned with cyclophosphamide/TBI for allogeneic
BMT
. Daily blood samples were collected each morning prior to, during, and for several days after TBI.
bFGF
levels in plasma of normal volunteers are 0.8-26 pg/ml.
bFGF
was below detectability in 22%, 30% and 45% of patients pre-TBI, during TBI or post-TBI respectively. Mean circulating plasma levels of
bFGF
decreased from a median of 52 pg/ml pre-TBI to 26 pg/ml during TBI, and to 5 pg/ml post-TBI. Among the 26 patients, 13 had more than one non-detectable plasma
bFGF
level, an additional five had at least one non-detectable level, and only eight patients had detectable levels in all daily samples. Naturally high levels of
bFGF
were observed in some patients undergoing fractionated TBI. In contrast, as many as 79% of patients had low
bFGF
levels in one or more samples. The impact of endogenous
bFGF
on the tolerance of normal tissues to irradiation is unknown, and warrants further study.
...
PMID:Circulating basic fibroblast growth factor declines during Cy/TBI bone marrow transplantation. 1038 50